PMID- 22954349
OWN - NLM
STAT- MEDLINE
DCOM- 20130317
LR  - 20151119
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 11
IP  - 6
DP  - 2012 Nov
TI  - A drug safety evaluation of everolimus in kidney transplantation.
PG  - 1013-22
LID - 10.1517/14740338.2012.722993 [doi]
AB  - INTRODUCTION: Calcineurin inhibitors (CNI) have greatly reduced the rate of acute 
      rejection and improved short-term graft survival after organ transplantation, 
      however, long-term survival has hardly changed since their introduction. CNIs are 
      believed to contribute to graft fibrosis, have side effects that adversely affect 
      cardiovascular risk, and are associated with an increased rate of post-transplant 
      malignancies. Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, is 
      not associated with graft fibrosis, has a superior cardiovascular risk profile to 
      CNI therapy and has shown potential for the prevention and treatment of diverse 
      forms of cancer. AREAS COVERED: This review summarizes key aspects of everolimus, 
      including its mechanism of action, pharmacokinetics, pharmacodynamics, drug-drug 
      interactions and pivotal clinical studies with a focus on safety and efficacy. 
      EXPERT OPINION: Everolimus is effective in improving graft function in selected 
      kidney transplant patients. Most adverse events are present for a short time 
      after the introduction of everolimus, and are manageable. Everolimus has the 
      potential to become an important agent in de novo and maintenance immunotherapy 
      in kidney transplant recipients.
FAU - Holdaas, Hallvard
AU  - Holdaas H
AD  - Oslo University Hospital, Department of Transplant Medicine, Section of 
      Nephrology, Rikshospitalet, Postbox 4950 Nydalen, N-0424 Oslo, Norway. 
      hallvard.holdaas@rikshospitalet.no
FAU - Midtvedt, Karsten
AU  - Midtvedt K
FAU - Asberg, Anders
AU  - Asberg A
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20120906
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Calcineurin Inhibitors)
RN  - 0 (Immunosuppressive Agents)
RN  - 9HW64Q8G6G (Everolimus)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Animals
MH  - Calcineurin Inhibitors
MH  - Clinical Trials as Topic
MH  - Drug Interactions
MH  - Everolimus
MH  - Graft Rejection/prevention & control
MH  - Graft Survival/drug effects
MH  - Humans
MH  - Immunosuppressive Agents/*adverse effects/pharmacology/therapeutic use
MH  - Kidney Transplantation/*methods
MH  - Sirolimus/adverse effects/*analogs & derivatives/pharmacology/therapeutic use
MH  - Time Factors
EDAT- 2012/09/08 06:00
MHDA- 2013/03/19 06:00
CRDT- 2012/09/08 06:00
PHST- 2012/09/08 06:00 [entrez]
PHST- 2012/09/08 06:00 [pubmed]
PHST- 2013/03/19 06:00 [medline]
AID - 10.1517/14740338.2012.722993 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2012 Nov;11(6):1013-22. doi: 10.1517/14740338.2012.722993. 
      Epub 2012 Sep 6.